Canaccord Genuity on Life Sciences/Biomedical Devices and Services: Take on Q4 and Beyond

Canaccord Genuity on Life Sciences/Biomedical Devices and Services: Dynamics of the diabetes industry into 2012: our take on Q4/11 and beyond

Analyst, William J. Plovanic, said, "Heading into the Q4/11 earnings season for diabetes technology and wound care, we remain long-term buyers of DexCom (Nasdaq: DXCM)(BUY), Insulet (Nasdaq: PODD)(BUY) and Derma Sciences (Nasdaq: DSCI)(BUY). However, we note that broader economic headwinds related to the decline in consumer confidence and high unemployment levels, in addition to patients working through higher insurance costs, may depress industry growth in the near term. Additionally, the broader wound care market is relatively insulated to economic pressures due to the non-discretionary nature of chronic wounds, and Derma Sciences is well positioned due to its differentiated advanced wound care portfolio and new product cycle."

---

Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!

You May Also Be Interested In

• Nomura Securities Maintains a 'Neutral' on Urban Outfitters (URBN); Staying Sidelined Despite Positive Q1 Surprises
• Barclays maintains an 'Equalweight' on Tech Data (TECD); Slight Adjustments on Q1 Results
• Nomura Securities Maintains a 'Buy' on Lowe's (LOW); Review of Q1

Create E-mail Alert Related Categories

Analyst Comments

Related Entities

Genuity Capital Markets, Earnings

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?

Follow StreetInsider.com On Twitter